Regulatory Affairs in Biosimilars EU vs US 2014
9 July, 2014
Palm Beach FL , USA
By the end of this decade, a significant number of blockbuster drugs will go off patent, allowing a large number of biosimilar products to enter the market.
- Learn about the latest global regulatory challenges and developments in biosimilar pharmaceutical products
- Analyze current regulatory requirements for biosimilars approval in Europe and USA and the future path of this legislation
- Review the variations between EU and US law and regulations and learn about the process for gaining scientific advice from the FDA and EMA
- Discuss what are the key differences between comparability and biosimilarity from a regulatory perspective
Exclusive Speaker Panel
Speaker Benita von Glahn
Liz Fuller
Cecil Nick
Sharon Longhurst, PhD
Catherine Akers
- Learn about the latest global regulatory challenges and developments in biosimilar pharmaceutical products
- Analyze current regulatory requirements for biosimilars approval in Europe and USA and the future path of this legislation
- Review the variations between EU and US law and regulations and learn about the process for gaining scientific advice from the FDA and EMA
- Discuss what are the key differences between comparability and biosimilarity from a regulatory perspective
Exclusive Speaker Panel
Speaker Benita von Glahn
Liz Fuller
Cecil Nick
Sharon Longhurst, PhD
Catherine Akers
Organizer
Kakushin Group
+421257272174
Related events
Regulatory Affairs in Biosimilars EU vs US 9 July, 2014